Project description DEENESFRITPL New solution brings relief to chronic lung disease sufferers The EU-funded STOP-COPD project has developed a novel device, called PulseHaler™, to treat chronic obstructive pulmonary disease (COPD), a progressive disease of the lungs. The device successfully opens the small airways, which are known to collapse in COPD patients, making it difficult for them to breathe. PulseHaler™ improves the exercise capacity, reduces breathlessness, and improves quality of life of COPD sufferers. Researchers will optimise the device with new features and functions and prepare it for large-scale manufacturing. Given the millions of COPD patients in Europe alone, the device has the potential to substantially reduce associated healthcare costs. Show the project objective Hide the project objective Objective Chronic Obstructive Pulmonary Disease (COPD) is a progressive, debilitating, disease of the lungs which affects 50M Europeans and kills 160,000 every year, with an annual cost burden of €141B. Respinova Ltd. has invented a novel device, called PulseHaler™, to treat COPD in a revolutionary way by opening the small airways, which are known to collapse in COPD patients thereby making it increasingly difficult to breathe. No other COPD treatment in the market today can effectively open the small airways. In a clinical trial, the PulseHaler™ was shown to substantially improve the functional capabilities and quality of life of COPD sufferers. If PulseHaler™ can reduce costs by the same magnitude to which it has been demonstrated to improve patient’s exercise capacity (the strongest predictor of morbidity and mortality), the current cost burden of COPD in Europe could be reduced by up to €21B annually.After winning a SMEi-1 grant and receiving a Seal of Excellence certificate for our first SMEi-2 application, we intend to complete several actions which will bring the PulseHaler™ to the commercial market in this SMEi-2 project. The design of the device will be finalized incorporating features and functions identified in our successful SMEi-1 project. We will then prepare the PulseHaler™ for large scale manufacturing. We will test the PulseHaler™ in a clinical study of COPD patients across several sites, to gather additional efficacy and usability data identified by KOLs in SMEi-1 as important to support uptake of the product in the market. We will continue to develop our reimbursement strategy for initial markets, finalize distribution arrangements in those markets, obtain regulatory approval, and proceed to launch the PulseHaler™. Respinova Ltd. is a 10 year old SME based in Israel with 7 employees. We have a seasoned management team with decades of combined medical device, business and leadership experience. Fields of science social sciencessociologydemographymortality Keywords Chronic Obstructive Pulmonary Disease respiratory disease lung disease medical device airway constriction small airways loss of lung function Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-2 Funding Scheme SME-2 - SME instrument phase 2 Coordinator RESPINOVA LTD Net EU contribution € 2 414 365,63 Address 8 HACHOSHLIM ST. 4672408 Herzliya Pituach Israel See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 3 449 093,75
